Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists

Autor: Hanis H. Zulkifly, Daniele Pastori, Deirdre A. Lane, Gregory Y. H. Lip

Publikováno v: Zulkifly, H H, Pastori, D, Lane, D A & Lip, G Y H 2023, ' Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists ', Journal of Clinical Medicine, vol. 12, no. 3, 1141 . https://doi.org/10.3390/jcm12031141
Journal of Clinical Medicine
Volume 12
Issue 3
Pages: 1141

Background: Good quality anticoagulation among patients with operated valvular heart disease is needed to reduce ischaemic and thromboembolic complications. There is limited evidence regarding factors that affect anticoagulation control in patients i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4776894820ba5b15db3b0a70dd23720d
https://vbn.aau.dk/da/publications/f17c6746-8fd2-4ff7-beab-fed0bfbe31af

University Teknologi MARA Researcher Publishes New Study Findings on Atrial Fibrillation (Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving ...).

Publikováno v: Heart Disease Weekly; 2/20/2023, p379-379, 1p